ALCYON

Calm passage

Functional antibody, delivered where the gut needs it.

Alcyon is building orally delivered avian antibodies (IgY) on three capabilities: antigen design, functional IgY and protected oral delivery. Norovirus is our first indication.

Read the science Partner and investor enquiries
IgY: core programme OMV: exploratory · Research and development stage. No product on the market.

Platform

Three capabilities, one working chain

An oral antibody is only as useful as the binding function that survives the journey. Each capability is designed to protect that function at a different point.

01

Antigen selection and design

The antigen used to immunise hens is intended to set the specificity and breadth of the antibody. It is designed upstream, as a source of differentiation in its own right.

02

Functional IgY

Polyclonal avian antibody recovered from egg yolk, at scale and without bleeding animals, with processing designed to keep binding function and not just protein mass.

03

Protected oral delivery

Antibody spread through a carbohydrate and amino-acid matrix, with an enteric film on every particle rather than on the capsule.

First indication

Norovirus is a problem of the gut lumen

Norovirus establishes infection at the intestinal epithelium. That makes the gut lumen the place where material has to be present, and closed settings such as voyages make the exposure window bounded and known in advance.

Our science page sets out the difference between active and passive immunity, where oral IgY fits, and how we plan to measure function rather than just mass.

Active vs passive immunity →
Schematic: active immunity builds over weeks and persists, while passive immunity is present only while dosed across a bounded exposure window. Illustrative only, no measured data.

The name

Why Alcyon

In Greek myth, Alcyone became the kingfisher, and for her sake the winds dropped for a few days each winter so the sea stayed calm. These became the halcyon days: a bounded, known window of calm passage.

The mark brings together the egg, which is the source of IgY, the kingfisher, and a calm horizon.

How we write

Mechanism before benefit

We separate what is established science, what our platform is designed to do, and what is still exploratory. Each is labelled. No result is presented as obtained before it exists.

  • Established science
  • Designed capability
  • Exploratory

We make no claim that any Alcyon product prevents, treats, cures or reduces the risk of any disease. Claims statement.

Contact

Talk to us

For cruise and institutional partners, investors, and scientific collaborators or candidates. Choose a route and we will send your message to the right person.

We aim to reply within five working days.